

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate reduction in the risk of disease progression or death with datopotamab deruxtecan compared to investigator's choice of chemotherapy for patients with previously treated advanced HR-positive, HER2-negative breast cancer in the Phase III TROPION-Breast01 study?
  - a. 12%
  - b. 37%
  - c. 68%
2. Which therapy yielded the greater reduction in the risk of disease progression or death among patients with ESR1 mutations in the Phase III EMBER-3 trial evaluating imlunestrant as monotherapy or combined with abemaciclib versus standard endocrine therapy for patients with ER-positive, HER2-negative advanced breast cancer pretreated with endocrine therapy?
  - a. Standard endocrine therapy
  - b. Imlunestrant monotherapy
  - c. Imlunestrant + abemaciclib
  - d. Imlunestrant monotherapy and imlunestrant with abemaciclib yielded similar benefit
3. Which progression-free survival (PFS) outcome was observed in the Phase II SERENA-2 study comparing 2 dose levels of camizestrant to fulvestrant for postmenopausal patients with ER-positive, HER2-negative advanced breast cancer?
  - a. Inferior PFS with both doses of camizestrant
  - b. No significant difference in PFS
  - c. A statistically significant improvement in PFS with the camizestrant 75 mg dose only
  - d. A statistically significant improvement in PFS with the camizestrant 150 mg dose only
  - e. A statistically significant improvement in PFS with both doses of camizestrant
4. What was the approximate median PFS reported with inavolisib, palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer in the INAVO120 Phase III study?
  - a. 5 months
  - b. 9 months
  - c. 15 months
  - d. 26 months
5. What was the approximate median PFS reported with datopotamab deruxtecan in the Phase III TROPION-Breast01 study for patients with previously treated HR-positive, HER2-negative advanced breast cancer?
  - a. 3.4 months
  - b. 6.9 months
  - c. 10.7 months